16.04.2012 - The Polish government is to ban Monsanto's MON810 maize making it the seventh in the club of EU countries to stop cultivation of the GM crop.
Warsaw – The move follows protests in Warsaw last month by around 1,500 beekeepers and anti-GM protesters who dumped thousands of dead bees on the steps of the Ministry of Agriculture. Agriculture Minister Marek Sawicki has announced that the government would implement a ban on the cultivation of the genetically modified MON 810 maize. The minister claimed the pollen might be responsible for a host of health problems and may even be the cause of the dwindling bee population. The government now wants to pass a law that circumvents the need to obtain EU approval for a ban on any GMO crops. Revised Polish regulations would stipulate that the ban may be implemented and that it will suffice simply to notify the European Commission of the matter. “We are pleasantly surprised that the government is looking for a way of actually implementing the ban,” said Greenpeace spokesman Jacek Winiarski after having a discussion with governmental representatives. If Poland implements the ban, it will follow in the footsteps of Austria, France, Germany, Greece, Hungary and Luxembourg which have all banned the cultivation of MON 810 at different stages, saying it threatens biodiversity.
25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.
21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.
11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.
04.08.2015 In a deal worth US$65m upfront, AstraZeneca is again teaming up with long-time partner Isis Pharmaceuticals Inc., this time to discover and develop RNA antisense drugs for cardiovascular, metabolic and renal diseases.
The BioShake series contains high-speed mixer and thermal mixer for small and very small volumes in microplates and reaction tubes and allows for the first time high precise and efficient mixing in the microliter scale for a wide range of applications. more